Leerink Swann Downgrades Pharmasset (VRUS) to Market Perform; A Befitting End to a Remarkable Biotech Story
Tweet
Share
E-mailGet Alerts VRUS Hot Sheet
Price: $0.00 --0%
Rating Summary:
3 Buy, 10 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 16 | New: 37
Rating Summary:
3 Buy, 10 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 16 | New: 37
Join SI Premium – FREE
Leerink Swann downgraded Pharmasset (NASDAQ: VRUS) from Outperform to Market Perform, price target raised from $100 to $137.
Leerink analyst says, "Bottom Line: We believe the acquisition of Pharmasset by Gilead (Nasdaq: GILD) announced yesterday validates our bullish outlook for the transformation in hepatitis C treatment and prospects of interferon-free regimens. The acquisition price of ~$11B likely sets a record for valuation of a development-stage company that could be more than 10x the previous largest similar acquisition that we can think of (acquisition of Cougar Biotechnology by Johnson and Johnson (NYSE: JNJ)). As a result of the announcement of the acquisition -- unanimously approved by VRUS's board of directors -- we are downgrading VRUS shares."
For an analyst ratings summary and ratings history on Pharmasset click here. For more ratings news on Pharmasset click here.
Shares of Pharmasset closed at $134.14 yesterday.
Leerink analyst says, "Bottom Line: We believe the acquisition of Pharmasset by Gilead (Nasdaq: GILD) announced yesterday validates our bullish outlook for the transformation in hepatitis C treatment and prospects of interferon-free regimens. The acquisition price of ~$11B likely sets a record for valuation of a development-stage company that could be more than 10x the previous largest similar acquisition that we can think of (acquisition of Cougar Biotechnology by Johnson and Johnson (NYSE: JNJ)). As a result of the announcement of the acquisition -- unanimously approved by VRUS's board of directors -- we are downgrading VRUS shares."
For an analyst ratings summary and ratings history on Pharmasset click here. For more ratings news on Pharmasset click here.
Shares of Pharmasset closed at $134.14 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Sandler: PFA survey is most positive for Medtronic, Inc. (MDT)
- BNP Paribas Exane Downgrades Lanxess AG (LXS:GR) (LNXSF) to Underperform
- Piper Sandler Downgrades Weave Communications Inc (WEAV) to Neutral
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
